HAEMATOKINE
LIVE

Serial Number

79313038

Owner

Faron Pharmaceuticals Oy

Attorney

Mark E. Olds

Filing Date

Feb 5, 2021

Add to watchlist:

No watchlists yet
View on USPTO

HAEMATOKINE Trademark

Serial Number: 79313038 • Registration: 6823077

HAEMATOKINE is a trademark filed by Faron Pharmaceuticals Oy on February 5, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Faron Pharmaceuticals Oy (13 trademarks)

Joukahaisenkatu 6

Entity Type: 09

Trademark Details

Filing Date

February 5, 2021

Registration Date

August 23, 2022

Published for Opposition

June 7, 2022

Goods & Services

Pharmaceuticals, medical and veterinary preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Sanitary preparations for medical purposes; Stem cells for medical or veterinary use; Stem cells for medical purposes; Tumor suppressing agents; Pharmaceutical preparations, namely, antineoplastics; Anti-neoplastic preparations of chemical origin, namely, pharmaceutical preparations for hematological malignancies, bone marrow dysfunction or suppressions; Anti-neoplastic preparations of microbial origin, namely, pharmaceutical preparations for hematological malignancies, bone marrow dysfunction or suppressions; Anti-cancer preparations; Compounds for treating cancer, namely, anti-cancer preparations; Antibodies for medical purposes for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Antibodies for medical use to treat inflammation and cancer growth and spread; Adjuvants for medical purposes; Vaccine adjuvants; Biological adjuvants for medical purposes; Anti-inflammatories; Antigens, namely, tumour antigens for medical diagnostic purposes; Biological preparations for the treatment of cancer; Biopharmaceuticals for the treatment of cancer; Biotechnological preparations for medical use, namely, biological preparations for the treatment of conditions associated with poor production of hematopoietic stem cells; Culture media for medical use, namely, culture media for use in augmentation of blood cells, bone marrow and tissues for medical purposes; Media for bacteriological cultures; Cell growth media for growing cells for medical use; Biological preparations for medical purposes, namely, biological preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Mixed biological preparations for medical purposes, namely, mixed biological preparations for the prevention and treatment of infectious diseases; Biological preparations for veterinary purposes, namely, biological preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations, namely, immunomodulators; Immunostimulants; Injectable pharmaceuticals for treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of bone diseases; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for activating cellular function; Pharmaceutical preparations for immunity adjustment; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for treating malignant tumors; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the prevention of tumours; Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances with anti-inflammatory properties for treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the treatment of autoimmune disorders; Pharmaceutical preparations for use in hematology; Pharmaceutical preparations for the prevention of diseases of the immune system; Pharmaceutical preparations for the prevention of disorders of the immune system; Pharmaceutical preparations for the prevention of autoimmune diseases; Pharmaceutical preparations for the treatment of disorders caused by bacteria; Pharmaceutical preparations for the treatment of diseases caused by bacteria; Pharmaceutical preparations for the prevention of disorders of the respiratory system; Pharmaceutical preparations for the prevention of inflammatory disorders; Pharmaceutical preparations for the prevention of autoimmune disorders; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for use in tissue transplantation; Pharmaceutical products for the treatment of bone diseases; Regulatory proteins for medical use, namely, protein arrays for medical diagnosis purposes; Serotherapeutic medicines, namely, pharmaceutical preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Synthetic peptides for pharmaceutical purposes for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical products for treating respiratory diseases; Pharmaceutical compounds for treating respiratory diseases; Pharmaceutical preparations for treating respiratory diseases; Pharmaceutical compounds for treating correlated pulmonary syndromes; Pharmaceutical preparations for treatment and prevention of ischemic conditions, inflammation and organ damages resulting from tissue traumas, reperfusion injuries, cancer, cancer metastasis, inflammatory conditions and allergic conditions; Pharmaceutical preparations for treatment and prevention of multi-organ failure, acute lung injury and acute respiratory distress syndrome in adults, adolescents, children, infants and neonates

Chemicals for use in industry, science and photography, as well as in agriculture, horticulture and forestry, except fungicides, herbicides, insecticides and parasiticides; Biological preparations for use in industry and science; Media for cell culture for use in the biotechnological industry, namely, cell culture media for scientific and research use; Media for cell culture for use in non-medical research laboratories, namely, cell culture media for laboratory use; Biological preparation for use in cell cultures other than for medical or veterinary use; Culture media for microbiology, for scientific and research use; Cell growth media for growing cells for scientific use; Biological preparation for use in cell cultures, other than for medical or veterinary use; Cultures of cell media other than for medical or veterinary use, namely culture media for scientific and research use; Cultures of microorganisms, other than for medical and veterinary use; Blood culture media being cell culture media for scientific use; Biological preparations for use in cell cultures, other than for medical or veterinary purposes; Stem cells, other than for medical or veterinary purposes; Stem cells for scientific purposes; Stem cells for research purposes

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Sep 26, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 28, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 1, 2022 FICS
FINAL DISPOSITION PROCESSED
Dec 1, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 23, 2022 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 23, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 23, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 7, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jun 7, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 18, 2022 NONP
ELECTRONIC RECORD REVIEW COMPLETE
Apr 29, 2022 FIXD
CHANGE OF NAME/ADDRESS REC'D FROM IB
Apr 16, 2022 ADCH
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Apr 1, 2022 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 30, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 30, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 30, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 30, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 30, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 25, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 25, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 25, 2022 TROA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 18, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 18, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 18, 2022 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 18, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 18, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 18, 2022 COAR
REFUSAL PROCESSED BY IB
Oct 25, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 27, 2021 RFCS
REFUSAL PROCESSED BY MPU
Sep 27, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 9, 2021 RFCR
NON-FINAL ACTION WRITTEN
Sep 8, 2021 CNRT
ASSIGNED TO EXAMINER
Aug 30, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 16, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 12, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 10, 2021 REPR